GGrantIndex
Sort

48,018 grants matching immunotherapy

Validating the hybrid epithelial/mesenchymal state as a biomarker of treatment response and outcomes in head and neck cancer

$702,871
Sidharth Venkata Puram · Washington University · U01 · FY2025 · DE

Topical proprietary biologic to treat oral mucositis

$702,863
Christian Young · Allander Biotechnologies, Inc. · R44 · FY2018 · DE

Determining the role of neutrophils in anti-tumor immunity and immune-related adverse events in the context of T cell-based therapies

$702,748
Taha Merghoub · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA

Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC

$702,580
John V. Heymach · University Of Tx Md Anderson Can Ctr · U01 · FY2020 · CA

Targeting Tumor-Associated Macrophages to Treat Lymphoma

$702,495
Wendong Huang · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA

Targeting HIV-specific CAR T cells to the gut for the durable remission of HIV

$702,446
Pamela J Skinner · University Of Minnesota · R01 · FY2025 · DK

Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer

$702,262
Grinu Mathew · University Of Nebraska Medical Center · R01 · FY2025 · CA

Microfluidic Assessment of Clinical Outcomes in Preterm Newborns

$702,125
Lyle L Moldawer · University Of Florida · R01 · FY2017 · HD

Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer

$702,059
Benjamin G. Neel · New York University School Of Medicine · R01 · FY2025 · CA

Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients

$702,007
Cecilia Larocca · Brigham And Women'S Hospital · R37 · FY2023 · CA

Career Development in Pediatric and Medical Oncology

$701,719
Irwin Bernstein · Fred Hutchinson Cancer Research Center · K12 · FY2017 · CA

Precision imaging of the spatial regulators of the hybrid epithelial/mesenchymal state in head and neck cancer

$701,699
Shannon L Stott · Massachusetts General Hospital · R01 · FY2024 · DE

Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancer

$701,661
Priscilla Kaliopi Brastianos · Massachusetts General Hospital · R01 · FY2025 · CA

Johns Hopkins Rheumatic Diseases Resource-based Core Center (Johns Hopkins RDRCC)

$701,658
Antony Rosen · Johns Hopkins University · P30 · FY2025 · AR

Development of multinuclear MRI for image guided therapy of glioma patients

$701,639
Ovidiu C Andronesi · Massachusetts General Hospital · R01 · FY2025 · CA

Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)

$701,440
Robert J Gray · Dana-Farber Cancer Inst · U01 · FY2018 · CA

Immune reconstitution following autologous and allogeneic stem cell transplant

$701,433
Frances Hakim · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA

NCI X-ray free electron laser (XFEL) initiative

$701,422
Yun Xing M Wang · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancer

$701,408
Priscilla Kaliopi Brastianos · Massachusetts General Hospital · R01 · FY2024 · CA

Research Project 1 - Targeting the MAPK and PI3K pathways in melanoma PDX

$700,949
Meenhard Herlyn · Wistar Institute · U54 · FY2017 · CA

Immunologic Basis of Cow's Milk-Induced Hypersensitivities

$700,728
Hugh Sampson · Icahn School Of Medicine At Mount Sinai · U19 · FY2009 · AI

The COVID-19 and Cancer Consortium (CCC19) Registry

$700,645
Jeremy Lyle Warner · Rhode Island Hospital · U01 · FY2025 · CA

A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity

$700,561
Catherine Sibyl Diefenbach · New York University School Of Medicine · R01 · FY2025 · CA

Membrane-based vaccine with checkpoint blockade for triple negative breast cancer

$700,539
Kamal V. Kannan · Metaclipse Therapeutics Corporation · R44 · FY2017 · CA

The Epigenetic Enzyme CARM1 as a Negative Regulator of Dendritic cells and CD8 T cells in Melanoma

$700,514
Kai W Wucherpfennig · Massachusetts General Hospital · P01 · FY2024 · CA